Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...

The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...

Cancer Burden in Bangladesh: Insights From National Institute of Cancer Research & Hospital, 2014-2020 Hepatocellular carcinoma (HCC) is a major cause of cancer mortality in sub-Saharan Africa, with ...

An interview with Dr. John D. Gordan from the University of California, San Francisco, and Dr. Michal G. Rose from Yale Cancer Center and VA Connecticut Healthcare System on "Systemic Therapy for ...

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...

Introduction Risk Factors and High-Risk Populations Screening Tools Screening Recommendations References A cost-effectiveness model shows a ≥ 3-month gain in life expectancy at a cost of < $50,000 per ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised as a systemic disorder driven ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...

Only one out of every five adults with cirrhosis in safety-net health systems receive guideline-concordant hepatocellular ...